title: Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors.
abstract: BACKGROUND
  Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.
  
  
  METHODS
  We described the treatment with this drug combination in a real-life cohort of 20 cirrhotic patients with genotype 1 who failed the triple therapy.
  
  
  RESULTS
  18 of them (90%) with Child-Pugh A, 11 (55%) with genotype 1a, 17 (85%) with more than 1 and 8 (40%) with more than 2 previous failed treatment; all patients had at baseline NS3 resistance-associated variants related to triple therapy failure. RBV was not administered due to anemia in previous treatments. The sustained virological response was 100%.
  
  
  CONCLUSIONS
  Treatment with SOF + DCV without RBV for 24 weeks is safe and effective in cirrhotic patients who failed triple therapy with the first generation of protease inhibitors.
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy. lucio.boglione@unito.it.com.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy. lucio.boglione@unito.it.com.
authors.forename: Lucio
authors.initials: L
authors.lastname: Boglione
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Simone Mornese
authors.initials: SM
authors.lastname: Pinna
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Chiara Simona
authors.initials: CS
authors.lastname: Cardellino
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Amedeo
authors.initials: A
authors.lastname: De Nicolò
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Jessica
authors.initials: J
authors.lastname: Cusato
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Carcieri
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Cariti
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
authors.affiliation: Unit of Infectious Diseases, University of Turin, Turin, Italy.|Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149, Turin, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: D'Avolio
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use; D011759:Pyrrolidines; D000069474:Sofosbuvir / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011480:Protease Inhibitors; D011759:Pyrrolidines; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir
keywords: Cirrhotic; Daclatasvir; HCV; Protease inhibitors; Ribavirin